Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52

Inclusion Criteria: * Female patients aged 40 to 52 years (inclusive) with mastodynia and BI-RADS category 3. * The patient's written informed consent to participate in any study-related procedures. * According to the Investigator, the patient's ability to comply with all the requirements of the study protocol, i.e. the patient's ability to cooperate adequately. * Patients who do not have chronic diseases of the cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, respiratory system, skin in the decompensation stage. * Consent to use reliable, evidence-based contraceptive methods (double containing the following types: hormonal, barrier, intrauterine spiral, etc.) throughout the study (from the time of the Informed Consent to Visit 6) . Exclusion Criteria: * Hypersensitivity to the components of the IMP. * Burdened history of allergies. * Participation in another clinical study less than 90 days before signing the informed consent form. * History of cancer. * Pregnancy or lactation. * Administration of dopamine agonists, dopamine antagonists, oestrogens and antiestrogens, dopamine. * Secondary amenorrhoea within 6 months or more. * Surgical, pharmacological or physiological menopause (except hysterectomy). * The prolactin level is more than 80 ng/mL. * Other reasons which make the patient's participation in the study undesirable, according to the Investigator.